Approaches to transfusion therapy and iron overload in patients with sickle cell disease: Results of an international survey

Pediatric Hematology and Oncology

Volumn 28, Issue 1, 2011, Pages 37-42

  Vichinsky, Elliott P ^a   Ohene Frempong, Kwaku ^b   Thein, Swee Lay ^c   Lobo, Clarisse Lopes De Castro ^d   Inati, Adlette ^e   Thompson, Alexis A ^f   Smith Whitley, Kim ^b   Kwiatkowski, Janet L ^b   Swerdlow, Paul S ^g   Porter, John B ^h   Marks, Peter W ⁱ  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d HEMORIO   (Brazil)

^e RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^f CHILDREN'S MEMORIAL HOSPITAL   (United States)

^g KARMANOS CANCER INSTITUTE   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

iron overload; sickle cell disease; transfusion therapy

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ACUTE CHEST SYNDROME; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHELATION THERAPY; CHRONIC LUNG DISEASE; DRUG INTERMITTENT THERAPY; FERRITIN BLOOD LEVEL; HEALTH SURVEY; HEART DISEASE; HEMOSIDEROSIS; HIGH RISK PREGNANCY; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER BIOPSY; PAIN; PATIENT MONITORING; PHYSICIAN; PRESCRIPTION; PRIAPISM; PRIMARY PREVENTION; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; STROKE; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; INTERNATIONALITY; IRON CHELATING AGENTS; IRON OVERLOAD; QUESTIONNAIRES; YOUNG ADULT;

EID: 79952149367     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2010.505497     Document Type: Article

References (16)

1. National Institutes of Health (NHLBI). The Management of Sickle Cell Disease. Bethesda, MD: National Institutes of Health; 2002. NIH publication no 02-2117.
2. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5-11. (Pubitemid 28304491)
3. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease.N Engl J Med. 2005;353:2769-2778.
4. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patientswith SCD or beta thalassemia. Am J Hematol. 2005;80:70-74. (Pubitemid 41254272)
5. Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81:858-863. (Pubitemid 44682188)
6. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054:40-47. (Pubitemid 43031009)
7. Modell B, Khan M, Darlison M. Survival in β-thalassaemiamajor in the UK: data from the UKT halassaemia Register. Lancet. 2000;355:2051-2052. (Pubitemid 30339248)
8. Silliman CC, Peterson VM, Mellman DL, et al. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. J Lab Clin Med. 1993;122:48-54. (Pubitemid 23206873)
9. Cohen AR, Martin MB. Iron chelation therapy in sickle cell disease. Semin Hematol. 2001;38(Suppl 1):69-72. (Pubitemid 32110274)
10. Voskaridou E, Douskou M, Terpos E, et al.Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol. 2005;84:434-440. (Pubitemid 40867919)
11. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2006;136:501-508. (Pubitemid 46046309)
12. Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol. 2003;120:744-752. (Pubitemid 36315093)
13. Ballas SK. Treatment of pain in adults with sickle cell disease. Am J Hematol. 1990;34:49-54. (Pubitemid 20139487)
14. Rogers ZR, lieff S, McMurray M, et al. Collaborative data project [C-DATA] of the comprehensive sickle cell centers program. Blood. 2006;108(11):Abstract 1200.
15. Cappellini MD.Overcoming the challenge of patient compliance with iron chelation therapy. Semin Hematol. 2005;42:S19-S21.
16. Treadwell M, Sung J, Murray E, et al. Barriers to deferoxamine adherence for adults with sickle cell disease. Blood. 2004;104(11):Abstract 3760.